Several new analogues of polyadenylic acid [(A)n], i.e. poly(2-fluoroadenylic acid) [(fl2A)n], poly(2-chloroadenylic acid [(cl2A)n], poly(2-bromoadenylic acid) [(br2A)n] and poly(2-iodoadenylic acid) [(io2A)n] have been synthesized and evaluated for their effects on the RNA-directed DNA polymerase (reverse transcriptase) activity of Moloney murine leukaemia virus. All (A)n analogues were found to be potent inhibitors of reverse transcriptase, the order of (decreasing) potency being (fl2A)n greater than (io2A)n greater than (br2A)n greater than (cl2A)n. For all four (A)n analogues the inhibition of reverse transcriptase was competitive with respect to the template-primer. (A)n . oligo(dT). The K1 values were 0.02 microgram/ml for (fl2A)n, 0.1 microgram/ml for (io2A)n, 0.5 microgram/ml for (br2A)n and 8 microgram/ml for (cl2A)n. With a Ki of 0.02 microgram/ml (approx. 0.04 microM), (fl2A)n can be considered as one of the most, if not the most, potent polynucleotide inhibitor of reverse transcriptase that has been described so far.
Stem cell-based gene therapy of HIV infection aims at inhibiting HIV replication and the progression to AIDS by the introduction of antiviral genes in primitive hematopoietic stem cells (HSC). Ideally, after differentiation into mature blood cells, these antiviral genes should create a host-cell population that is resistant to HIV infection. Although the current gene therapy clinical trials established the safety and provided proof-of-principle for gene therapy of HIV-1 infection, the overall results have been disappointing, and many issues still remain to be resolved before this approach can be efficiently used against HIV infection. Since a significant percentage of the stem cells in the patient have to be transduced to obtain a significant impact on HIV replication, the first prerequisite for successful gene therapy of HIV-1 infection consists of increasing the amount of transduced HSCs. Further improvements in gene transfer and gene therapy strategies will probably lead to future clinical successes. On the other hand, HIV-1 infection is a very complex disease, affecting various organs in addition to the T-cells, with an impact on T-cell homeostasis that is currently not fully understood. Even at low viral loads and before the advent of clinical symptoms, a high turnover of CD4+ cells exists in HIV-infected patients with functional implications for the homeostasis of the thymus, bone marrow and T-cell homeostasis which may hamper the CD34+ HSC approach. Hence, the extent to which these alterations hamper a gene therapy approach, or can be reversed upon HAART, will determine the feasibility of future gene therapy against AIDS.
Oral (E)-5-(2-bromovinyl)-2'deoxyuridine in severe herpes zoster (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) is a nucleoside analogue that inhibits the replication of herpes simplex virus type 1 (HSV-1) in cell culture (primary rabbit kidney) at a concentration of 0 01 mg/l, but does not affect normal cell metabolism at concentrations up to 100 mg/I.' BVDU has also been found effective in the local and systemic treatment of HSV-1 skin lesions, and its associated mortality,